128:
41:
188:
Bordet, T.; Buisson, B.; Michaud, M.; Drouot, C.; Galea, P.; Delaage, P.; Akentieva, N. P.; Evers, A. S.; Covey, D. F.; Ostuni, M. A.; Lacapere, J.-J.; Massaad, C.; Schumacher, M.; Steidl, E.-M.; Maux, D.; Delaage, M.; Henderson, C. E.; Pruss, R. M. (2007). "Identification and
Characterization of
426:
Bordet, T.; Buisson, B.; Michaud, M.; Abitbol, J.-L.; Marchand, F.; Grist, J.; Andriambeloson, E.; Malcangio, M.; Pruss, R. M. (2008). "Specific
Antinociceptive Activity of Cholest-4-en-3-one, Oxime (TRO19622) in Experimental Models of Painful Diabetic and Chemotherapy-Induced Neuropathy".
353:
Rovini, Amandine; Carré, Manon; Bordet, Thierry; Pruss, Rebecca M.; Braguer, Diane (2010). "Olesoxime prevents microtubule-targeting drug neurotoxicity: Selective preservation of EB comets in differentiated neuronal cells".
493:
488:
385:"Olesoxime (cholest-4-en-3-one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel"
498:
152:
by three scientists: Christopher
Henderson, Olivier Pourquie and Jean-Louis Kraus, and two entrepreneurs: Antoine Beret and Michel Delaage. Trophos' lead compound was
483:
280:"Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)"
302:
503:
508:
478:
141:
was a biopharmaceutical company specialising in the discovery and development of novel therapeutics to treat both orphan
334:
142:
232:
310:
27:
40:
127:
452:
258:"Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy"
214:
189:
Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug
Candidate for Amyotrophic Lateral Sclerosis".
444:
414:
371:
206:
160:
113:
383:
Xiao, Wen Hua; Zheng, Felix Y.; Bennett, Gary J.; Bordet, Thierry; Pruss, Rebecca M. (2009).
156:(TRO19622), a mitochondrial targeted compound developed to treat neurodegenerative diseases.
436:
404:
396:
363:
198:
171:
350,000,000 in milestone performance payments. The deal was completed shortly afterwards.
473:
409:
384:
467:
456:
218:
279:
257:
400:
367:
440:
202:
153:
149:
52:
448:
418:
375:
210:
332:
Staff (15 February 2015). "Roche to Buy
Trophos for Up-to-$ 543M".
303:"Roche buys France's Trophos to expand in neuromuscular disease"
168:
164:
429:
191:
119:
108:
93:
67:
48:
33:
23:
494:Pharmaceutical companies disestablished in 2015
37:research and development in biotechnology
338:(paper). Vol. 35, no. 4. p. 6.
8:
489:Pharmaceutical companies established in 1999
335:Genetic Engineering & Biotechnology News
18:
163:announced its intention to buy Trophos for
126:
39:
17:
408:
499:French companies disestablished in 2015
180:
145:diseases and more prevalent disorders.
260:. ClinicalTrials.gov. 5 February 2010
7:
484:French companies established in 1999
301:Franklin, Joshua (16 January 2015).
14:
148:Trophos was founded in 1999 in
282:. ClinicalTrials.gov. May 2010
237:UKMi New Drugs Online Database
167:120,000,000 upfront and up to
1:
504:2015 mergers and acquisitions
509:Companies based in Marseille
479:Defunct companies of France
525:
401:10.1016/j.pain.2009.09.006
368:10.1016/j.bcp.2010.04.018
356:Biochemical Pharmacology
441:10.1124/jpet.108.139410
203:10.1124/jpet.107.123000
28:Privately held company
74:Christopher Henderson
313:on 15 December 2015
20:
161:Hoffmann-La Roche
159:In January 2015,
143:neurodegenerative
136:
135:
114:Hoffmann-La Roche
516:
460:
422:
412:
379:
340:
339:
329:
323:
322:
320:
318:
309:. Archived from
298:
292:
291:
289:
287:
276:
270:
269:
267:
265:
254:
248:
247:
245:
243:
229:
223:
222:
185:
131:
130:
104:
102:
80:Jean-Louis Kraus
77:Olivier Pourquie
62:
60:
44:
43:
21:
524:
523:
519:
518:
517:
515:
514:
513:
464:
463:
425:
382:
352:
349:
347:Further reading
344:
343:
331:
330:
326:
316:
314:
300:
299:
295:
285:
283:
278:
277:
273:
263:
261:
256:
255:
251:
241:
239:
231:
230:
226:
187:
186:
182:
177:
132:
125:
100:
98:
89:
58:
56:
38:
12:
11:
5:
522:
520:
512:
511:
506:
501:
496:
491:
486:
481:
476:
466:
465:
462:
461:
435:(2): 623–632.
423:
395:(1–3): 202–9.
380:
362:(6): 884–894.
348:
345:
342:
341:
324:
293:
271:
249:
224:
197:(2): 709–720.
179:
178:
176:
173:
134:
133:
123:
121:
117:
116:
110:
106:
105:
95:
91:
90:
88:
87:
86:Michel Delaage
84:
81:
78:
75:
71:
69:
65:
64:
55:, France (1999
50:
46:
45:
35:
31:
30:
25:
13:
10:
9:
6:
4:
3:
2:
521:
510:
507:
505:
502:
500:
497:
495:
492:
490:
487:
485:
482:
480:
477:
475:
472:
471:
469:
458:
454:
450:
446:
442:
438:
434:
430:
424:
420:
416:
411:
406:
402:
398:
394:
390:
386:
381:
377:
373:
369:
365:
361:
357:
351:
350:
346:
337:
336:
328:
325:
312:
308:
304:
297:
294:
281:
275:
272:
259:
253:
250:
238:
234:
228:
225:
220:
216:
212:
208:
204:
200:
196:
192:
184:
181:
174:
172:
170:
166:
162:
157:
155:
151:
146:
144:
140:
129:
122:
118:
115:
111:
107:
96:
92:
85:
83:Antoine Beret
82:
79:
76:
73:
72:
70:
66:
54:
51:
47:
42:
36:
32:
29:
26:
22:
16:
432:
428:
392:
388:
359:
355:
333:
327:
315:. Retrieved
311:the original
306:
296:
284:. Retrieved
274:
262:. Retrieved
252:
240:. Retrieved
236:
227:
194:
190:
183:
158:
147:
138:
137:
124:France
120:Headquarters
112:Acquired by
24:Company type
15:
317:30 December
233:"olesoxime"
468:Categories
175:References
286:3 October
264:3 October
242:2 January
154:olesoxime
150:Marseille
53:Marseille
457:33726393
449:18492948
419:19833436
376:20417191
219:17271734
211:17496168
34:Industry
410:2787910
307:Reuters
139:Trophos
99: (
94:Defunct
68:Founder
57: (
49:Founded
19:Trophos
455:
447:
417:
407:
374:
217:
209:
474:Roche
453:S2CID
215:S2CID
445:PMID
415:PMID
389:Pain
372:PMID
319:2015
288:2010
266:2010
244:2016
207:PMID
109:Fate
101:2015
97:2015
59:1999
437:doi
433:326
405:PMC
397:doi
393:147
364:doi
199:doi
195:322
470::
451:.
443:.
431:.
413:.
403:.
391:.
387:.
370:.
360:80
358:.
305:.
235:.
213:.
205:.
193:.
459:.
439::
421:.
399::
378:.
366::
321:.
290:.
268:.
246:.
221:.
201::
169:€
165:€
103:)
63:)
61:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
